[go: up one dir, main page]

MX2019004894A - Administración de agente activo de la mucosa. - Google Patents

Administración de agente activo de la mucosa.

Info

Publication number
MX2019004894A
MX2019004894A MX2019004894A MX2019004894A MX2019004894A MX 2019004894 A MX2019004894 A MX 2019004894A MX 2019004894 A MX2019004894 A MX 2019004894A MX 2019004894 A MX2019004894 A MX 2019004894A MX 2019004894 A MX2019004894 A MX 2019004894A
Authority
MX
Mexico
Prior art keywords
active agent
agent delivery
mucosal
mucosal active
composition
Prior art date
Application number
MX2019004894A
Other languages
English (en)
Inventor
Worth Carol
Baride Kalpana
Original Assignee
Suda Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016904449A external-priority patent/AU2016904449A0/en
Application filed by Suda Ltd filed Critical Suda Ltd
Publication of MX2019004894A publication Critical patent/MX2019004894A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un método para aumentar la penetración de agentes activos a través de membranas de la mucosa, el método que comprende la etapa de: a) administrar a un sujeto que lo necesita una composición que comprende: i) uno o más hidrótropos en una cantidad total de menos de 15 % en peso de la composición; y ii) un agente activo con un coeficiente de partición (logP) o coeficiente de distribución (logD) de entre 0 y 5.
MX2019004894A 2016-10-31 2017-10-30 Administración de agente activo de la mucosa. MX2019004894A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2016904449A AU2016904449A0 (en) 2016-10-31 Mucosal Active Agent Delivery
PCT/AU2017/051193 WO2018076074A1 (en) 2016-10-31 2017-10-30 Mucosal active agent delivery

Publications (1)

Publication Number Publication Date
MX2019004894A true MX2019004894A (es) 2019-06-20

Family

ID=62023155

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004894A MX2019004894A (es) 2016-10-31 2017-10-30 Administración de agente activo de la mucosa.

Country Status (10)

Country Link
US (1) US11458201B2 (es)
EP (1) EP3532068A4 (es)
JP (1) JP2019536769A (es)
KR (1) KR20190082803A (es)
CN (1) CN109996547A (es)
AU (1) AU2017351744A1 (es)
BR (1) BR112019008565A2 (es)
CA (1) CA3041112A1 (es)
MX (1) MX2019004894A (es)
WO (1) WO2018076074A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
WO2025182691A1 (ja) * 2024-02-29 2025-09-04 株式会社ユニファイジャパン ５－デアザフラビン化合物含有乳剤およびその製造方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05221857A (ja) * 1992-02-14 1993-08-31 Arakusu:Kk 配合解熱鎮痛剤
AU721868B2 (en) * 1995-11-28 2000-07-13 Michael D. Wider Antimicrobial composition and methods of use therefor
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
TWI223598B (en) * 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
JP2000119198A (ja) * 1998-10-16 2000-04-25 Eisai Co Ltd 苦味等の隠蔽されたホスフォジエステラーゼ阻害剤含有経口製剤
JP2002041452A (ja) 2000-07-27 2002-02-08 Hitachi Ltd マイクロプロセッサ、半導体モジュール及びデータ処理システム
EP1343932B1 (en) * 2000-12-20 2004-08-18 Unilever N.V. Fabric cleaning system
US6660211B2 (en) * 2001-04-23 2003-12-09 Kimberly-Clark Worldwide, Inc. Methods of making biodegradable films having enhanced ductility and breathability
US20100204323A1 (en) 2004-12-09 2010-08-12 The Dial Corporation Antimicrobial compositions comprising organic acid esters and methods for reducing virus and bacterial populations using such compositions
JP5514270B2 (ja) * 2005-09-13 2014-06-04 ロート製薬株式会社 アシタザノラスト含有組成物
RU2008151178A (ru) 2006-05-24 2010-06-27 Дзе Дайл Корпорейшн (Us) Способы и изделия, обладающие сильным противовирусным и противобактериальным действием
RU2008152442A (ru) * 2006-06-05 2010-07-20 Дзей Дайл Корпорейшн (Us) Способы и изделия, имеющие высокую противовирусную и противобактериальную эффективность
JP2009544715A (ja) * 2006-07-28 2009-12-17 ノヴァデル ファーマ インコーポレイテッド 抗片頭痛の口腔噴霧製剤及び方法
CA2687085A1 (en) * 2007-05-10 2008-11-20 Novadel Pharma Inc. Anti-insomnia compositions and methods
US20110195042A1 (en) * 2010-02-10 2011-08-11 Thomas Edward Huetter Compositions, Methods and Kits Useful for Treating a Respiratory Symptom
GB201006200D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition
AU2011264941B2 (en) * 2010-06-07 2014-10-16 Suda Ltd Oral spray formulations and methods for administration of sildenafil
US9186321B2 (en) * 2011-12-05 2015-11-17 Suda Ltd. Oral spray formulations and methods for administration of sildenafil
ES2768323T5 (es) * 2012-10-12 2023-03-08 Oreal Composiciones cosméticas que contienen al menos un hidrótropo y al menos un compuesto activo
US20150250791A1 (en) * 2014-03-06 2015-09-10 Bhaskara Rao Jasti Combining sildenafil with caffeine in an oral disintegrating dosage form
US20160166543A1 (en) * 2014-12-10 2016-06-16 Hemant N. Joshi Stable combination oral liquid formulation of melatonin and an antihistaminic agent

Also Published As

Publication number Publication date
CA3041112A1 (en) 2018-05-03
AU2017351744A1 (en) 2019-05-02
WO2018076074A1 (en) 2018-05-03
EP3532068A1 (en) 2019-09-04
EP3532068A4 (en) 2020-04-29
CN109996547A (zh) 2019-07-09
US20190282697A1 (en) 2019-09-19
KR20190082803A (ko) 2019-07-10
US11458201B2 (en) 2022-10-04
JP2019536769A (ja) 2019-12-19
BR112019008565A2 (pt) 2019-07-09

Similar Documents

Publication Publication Date Title
MX2024013963A (es) Un antagonista de il-4r util para el tratamiento o la prevencion del asma
AR100925A1 (es) Composiciones orales que contienen fuentes de ión de zinc, estaño y fluoruro
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
CL2018000299A1 (es) Composiciones con potenciadores de impregnacion para el suministro de fármacos.
CL2015002677A1 (es) Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial.
MX383446B (es) Composiciones para el cuidado bucal.
CO7111300A2 (es) Formulación de anticuerpos
MX2017013590A (es) Administracion de agente anticaspa soluble en surfactante.
CO7151487A2 (es) Formulación de anticuerpos
PE20141906A1 (es) Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
MX2016000271A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
MX2016006641A (es) Composición novedosa y método de uso para controlar patógenos y prevenir enfermedades en semillas.
PE20211069A1 (es) Composicion que comprende 5'-metilselenoadenosina, selenoadenosil-l-homocisteina y gama glutamil-metilselenocisteina
CR11418A (es) Trans-clomifeno para el sindrome metabolico
CR20180228A (es) Terapia adjunta con 25-hidroxi vitamina d y articulos de la misma
MX393613B (es) Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas.
MX2018015132A (es) Composiciones para el cuidado bucal.
CL2016002560A1 (es) Forma de dosificación farmacéutica sólida oral que comprende siponimod, un agente protector de la humedad y opcionalmente un excipiente farmacéutico; procedimiento de preparación.
MX2019002781A (es) Estabilizadores de mastocitos para el tratamiento de hipercitoquinemia e infeccion viral.
AR091039A1 (es) Composiciones farmaceuticas topicas que comprenden terbinafina, uso y metodo de tratamiento
MX2022001144A (es) Metodos y composiciones para modular la microbiota intestinal y para manejar el peso.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
DOP2016000007A (es) Pirazolpiridinas sustituidas
PE20191044A1 (es) Composicion farmaceutica